The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents


We compared overall survival (OS) of 1017 patients with newly diagnosed multiple myeloma (MM) who were treated with different novel agent-based induction regimens and who underwent early autologous stem cell transplant (ASCT). Subgroups were defined by type of induction therapy: cyclophosphamide–bortezomib–dexamethasone (CyBorD; n=193), bortezomib… (More)
DOI: 10.1038/bmt.2016.214


5 Figures and Tables